Methoxetamine & MAOI
Methoxetamine (MXE) is a dissociative drug, a structural analog of ketamine, and shares similar pharmacological properties. It acts as a noncompetitive antagonist of NMDA receptors, which are a specific type of receptor involved in the transmission of signals between neurons.
By binding to NMDA receptors, MXE blocks their normal activation by the neurotransmitter glutamate, reducing the transmission of signals in certain areas of the brain. This disruption of normal glutamate signaling can lead to alterations in perception, sensory distortions, and a dissociative state characterized by detachment from one's surroundings and a sense of disconnection from one's body (depersonalization and derealization). MXE also works like a serotonin-reuptake inhibitor.
Monoamine oxidase inhibitors (MAOIs) are a class of medications that work by inhibiting the enzyme monoamine oxidase. This enzyme is responsible for breaking down neurotransmitters like serotonin, dopamine, and norepinephrine in the brain. By inhibiting monoamine oxidase, MAOIs increase the levels of these neurotransmitters, which can have various effects on mood, behavior, and other physiological processes.
Types of MAOIs:
Non-selective MAOIs: These inhibit both types of monoamine oxidase, known as MAO-A and MAO-B. Examples include phenelzine, isocarboxazid, and tranylcypromine.
Selective MAO-A inhibitors: These mainly target MAO-A and have a lesser effect on MAO-B. Moclobemide is an example of a selective MAO-A inhibitor.
Selective MAO-B inhibitors: These primarily inhibit MAO-B, while having minimal effects on MAO-A. Selegiline and rasagiline are examples of selective MAO-B inhibitors.
When MXE and MAOIs are combined, there is an increased risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonin activity in the brain. It can manifest as symptoms such as agitation, confusion, rapid heartbeat, high blood pressure, dilated pupils, tremors, and in severe cases, seizures and loss of consciousness.
Another concern is a hypertensive crisis, which occurs when there is a significant rise in blood pressure. Combining MXE with MAOIs can increase the risk of hypertensive crisis, leading to severe headaches, chest pain, palpitations, and even the risk of stroke.
We have poorly confirmed information that MXE seems to exhibit enhanced potency when paired with MAO-B inhibitors. Although there are limited details accessible, it is worth noting that there have been unfavorable accounts linked to the combination of MAO-A inhibitors also.
In addition, due to the complexity and diversity of the effects of MSE and MAOIs on neurotransmitter levels, it can be unpredictable and can lead to other adverse reactions, such as mood changes, behavior disorders, sudden collapses, hallucinations, and cardiovascular complications.
All things considered, we recommend avoiding this combination under any conditions.
Last edited by a moderator: